Pfizer (PFE)

In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and market analysts alike. While the specifics of such an event remain a forward-looking conjecture, this article delves into the potential

Mumbai, India – September 27, 2025 – Abbott India Limited (NSE: ABBOTINDIA), a prominent player in the Indian pharmaceutical sector, is exhibiting a robust financial trajectory and a promising valuation outlook. Propelled by strong Q1 FY2025-2026 results and strategic market maneuvers, the company continues to solidify its position in the rapidly expanding

As the clock ticks towards midnight on September 30, 2025, the United States government stands on the precipice of a highly imminent and seemingly unavoidable shutdown. With just days left until the new fiscal year begins, partisan gridlock in Congress has stalled all efforts to pass a funding agreement, setting

The company continues to improve its pipeline.

You won't need a huge amount of cash to invest in these great pharma stocks.

Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet.

Pfizer Inc.

The pharmaceutical giant is again plunging headfirst into weight-loss drug development.

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly Big Pharma, remains displeased.

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

These dividend stocks offer high yields and growth catalysts that could support payouts for decades.

These stocks come with some uncertainty, but they have strong fundamentals and trade at low earnings multiples.

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.

Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr.

Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.

There's an opportunity to get in on the weight-loss drug craze at a reasonable price.

Pfizer needs to fortify its future revenues.

These blue chip dividend stocks offer both income and growth potential.

Investors once speculated that Pfizer might consider acquiring Viking.

The healthcare sector finds itself in turbulent waters in 2025, registering a concerning 5% slump and significantly lagging the overall S&P 500 index. This downturn marks a continuation of a multi-year trend of muted returns for a sector traditionally viewed as defensive and resilient. The underperformance is not merely

The company is accelerating plans to run Phase 3 testing of its non-vaccine flu prevention drug by six months.

Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.

Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.

The pharma giant may be heading for a new era of growth.